Through in vivo shRNA and CRISPR/Cas9 screens, the tumor suppressors ZMAT3 [35,37] and MLH1 [35] were identified as predominant TP53 target effectors to the TP53-mediated tumor suppression program. This evidence concerns the gene ZMAT3 and neoplasm.